TERN earnings analysis
What we found in TERN's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Terns is a clinical-stage oncology company focused on TERN-701 (an oral allosteric BCR‑ABL1 inhibitor) advancing toward pivotal development. The company received FDA Breakthrough Therapy Designation for TERN‑701 and has an announced Merck merger at $53.00 per share expected to close in Q2 2026; the 10‑K/A does not amend the financial statements. The filing emphasizes near‑term clinical milestones (pivotal dose selection/End of Phase 2 mid‑2026; Phase 3 2L+ initiation late 2026/early 2027) but contains no quantitative revenue or EPS guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Breakthrough Therapy Designation for lead asset
- The company disclosed (8‑K, Apr 27, 2026) FDA Breakthrough Therapy Designation for TERN‑701 in adult Ph+ CML in chronic phase (patients without the T315I mutation who were previously treated with two or more TKIs), with CARDINAL Phase 1/2 responses noted at week 24.
- Merger agreement provides strategic exit and value
- The March 24, 2026 Merck merger agreement offers $53.00 per share (as disclosed in the Form 10‑K), with the Offer/Merger expected to close in Q2 2026, which materially changes strategic optionality for shareholders.
- Near‑term clinical milestones timed for 2026
- The MD&A/Item 1 (Original 10‑K) sets pivotal dose selection/End of Phase 2 for mid‑2026 and Phase 3 (2L+) initiation in late 2026/early 2027, with updated CARDINAL data expected in H2 2026.
- Balance‑sheet and equity base disclosed
- The filing reports 115,521,157 shares outstanding as of April 17, 2026 and an aggregate market value of $324,170,335 as of June 30, 2025.
- Experienced leadership; CEO compensation aligned to 2025
- Amy Burroughs has served as CEO since February 2024; 2025 total compensation reported for the CEO was $4,589,929 (salary $645,000; option awards $3,416,541).
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Transaction closing and integration uncertainty
- The Form 10‑K describes transaction‑specific risks including uncertainty around closing the Merck offer expected in Q2 2026 and potential business disruption or litigation tied to the transaction.
- No approved products / clinical‑stage execution risk
- The company is clinical‑stage with no approved products (Original Filing disclosures); success depends on future clinical development and regulatory approvals.
- Narrow initial labeled population
- The Breakthrough Therapy Designation covers adult Ph+ CML in chronic phase for patients without the T315I mutation who were previously treated with two or more TKIs, a limited labeled population per the 8‑K disclosure.
- Early clinical data and development timing risk
- CARDINAL Phase 1/2 efficacy signals are based on week 24 data (as noted in the 8‑K), which is early and may not predict pivotal outcomes; pivotal dose selection and End of Phase 2 are targeted for mid‑2026.
- Liquidity / cash‑burn and negative EPS
- Quarterly diluted EPS have been negative recently (e.g., 2024Q1 -0.30, 2024Q2 -0.31, 2024Q3 -0.28, 2024Q4 -0.23; 2025Q1 -0.26 through 2025Q4 -0.24 per the provided quarterly history) and earlier free cash flow was negative (e.g., 2024Q1 FCF -$23M, 2024Q2 -$16M).
- Dependence on third parties and potential costs
- The 10‑K reiterates reliance on third parties for manufacturing and clinical conduct and discloses potential litigation and termination/reverse‑termination fees associated with the Merck transaction (amounts and timing contingent per the Original Filing).
What they reported.
What the company itself reported, taken out of the document.
- Segment
- Clinical‑stage oncology R&D (lead program: TERN‑701, an oral allosteric BCR‑ABL1 inhibitor)
What they said about what is next.
The MD&A and Item 1 discuss development milestones (pivotal dose selection/End of Phase 2 mid‑2026; updated CARDINAL data in H2 2026; Phase 3 2L+ initiation late 2026/early 2027) but the filing contains no quantitative revenue or EPS guidance; annual outlook is deferred to an earnings press release/call.
The filing reads better than the one before it.
What came before.
- 10-K · March 30, 2026
- Terns is a clinical-stage oncology company whose lead asset TERN-701 (an oral allosteric BCR-ABL1 inhibitor) is advancing toward pivotal development (pivotal dose selection/End of Phase 2 mid-2026; Phase 3 2L+…
- 10-Q · May 8, 2025
- Terns reported a net loss of $23,908,000 (net loss per share of $0.26) for the quarter ended March 31, 2025. Cash and marketable securities remain sizable at $139,023,000 and $195,241,000 respectively, but operating…
- 10-Q · August 5, 2024
- Terns reported no revenue and remains a clinical-stage company. For the three months ended June 30, 2024 the company widened losses: net loss was $22,736 thousand (EPS $(0.31)) versus $17,896 thousand (EPS $(0.25)) in…
- 10-K · March 14, 2024
- Terns is a clinical-stage biopharmaceutical company advancing small-molecule programs in oncology (CML) and metabolic disease (obesity, MASH). The company has multiple near-term clinical catalysts (interim CARDINAL data…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TERN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever